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Abstract
Telomeres are specialized functional complexes that protect the ends of eukaryotic 
chromosomes. The telomeric DNA sequences are tandem repeats of a short hexameric 
sequence unit. The inability to DNA polymerase to replicate the end of the chromosome 
during lagging strand synthesis results in the loss of telomeric repeats when cell divides. 
Telomere shortening provides a barrier to cancer progression and the majority of the can-
cer cells depend on the activation of telomerase to gain proliferative immortality. Thus, 
telomerase is a molecular target for diseases since its discovery. Telomerase inhibition 
enables more specific ground for cancer therapy because the telomerase is not detected 
in most normal tissues. Some of the synthetic and natural telomerase inhibitors were 
tried on various cancer cells and there was a decrease in the number of cancer cells. But 
on the other hand, telomere shortening correlates with cellular aging. Some evidence 
suggests that the progressive loss of telomeric repeats of chromosomes may function as 
a molecular clock that triggers senescence. Telomerase-related gene mutations also result 
in some diseases. Because of this, telomerase activators are important for antiaging and 
telomerase-dependent disease treatments. This chapter summarizes the pharmaceutical 
importance of telomeres, telomerase structure, telomerase  activators, and inhibitors.
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1. Introduction
1.1. Importance of telomeres
Telomeres are specialized functional complexes that protect the ends of eukaryotic chromo-
somes. The telomeric DNA sequences are, in most species, tandem repeats of a short hexameric 
sequence unit [1]. Overall, telomere sizes range from about 15 to 20 kbp at birth to  sometimes less 
than 5 kbp in chronic disease states. Telomeric repeats help maintain  chromosomal  integrity [2]. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Evolutionary conservation of this repetitive DNA sequence family might indicate that sequence 
is essential to the cellular function [3]. Telomeric DNA sequences and structure are simi-
lar among otherwise widely divergent eukaryotes. The telomeric repeat unit is TTAGGG for 
humans as well as other vertebrates [4]. The ends of telomeres are protected and regulated by 
telomere binding proteins and form a t loop structure [2, 5]. Mainly, the inability of DNA poly-
merase to replicate the end of the chromosome during lagging strand synthesis results in the 
loss of telomeric repeats when cell divides. This phenomenon eventually results in a growth 
arrest and telomeres become critically shortened when multiple chromosome end fusions occur, 
resulting in a loss of cell viability [2]. Telomere shortening provides a barrier to cancer progres-
sion by preventing immortalization and the majority of the cancer cells depend on the activation 
of telomerase to gain proliferative immortality [2, 6]. But on the other hand, telomere shortening 
correlates with cellular aging. Stem and progenitor cells express low  levels of telomerase [6].
1.2. Telomerase structure and function
Greider and Blackburn identified a specialized DNA polymerase in extracts from the 
Tetrahymena that extends the chromosome ends in eukaryotes [7]. Telomerase adds multiple 
copies of certain DNA unit to the terminal portion of one strand of the repeat tract [1, 4]. This 
process is required for genomic stability and cell viability. Telomerase is a specialized reverse 
transcriptase. Telomerase subunit TER identified in the late 1980s and catalytic subunit TERT 
in 1997. Subsequent studies showed that the TER and TERT together form a tight complex 
that is sufficient for telomeric DNA repeat synthesis in vitro [6]. TER contains RNA template 
for reverse transcription [8–10]. TERT contains discrete domains that carry out the mechani-
cally complicated reaction of nucleic acid and nucleotide binding and selectivity in a coordi-
nated manner during telomerase replication [8]. Despite only TERT and TER are required for 
telomerase catalytic activity in vitro, the physiologically functional holoenzyme is a multisub-
unit ribonucleoprotein (RNP). Tetrahymena telomerase holoenzyme contains eight subunits, 
each of which is essential for telomere length  maintenance [10].
Telomerase is a very important enzyme for the aging process and carcinogenesis. Primary 
human cells exhibit limited replicative potential but the cancer cell lines are immortal with 
passage in culture [11]. In embryonic stem cells telomerase is activated and maintains telo-
mere length but the level of telomerase activity is low or absent in the majority of the stem 
cells. Thus, even in stem cells, except embryonic stem cells and cancer stem cells, telomere 
shortening occurs, possibly at a slower rate than that in normal somatic cells [12].
To grow indefinitely, human cancer cells must compensate the progressive loss of telo-
meric DNA by cell division [13]. This immortality is mainly a result of telomerase activity. 
Telomerase is expressed in more than 85% of cancer cells [14–17], but in some cells, the telo-
mere length could be maintained in the absence of telomerase. It has been deduced that one 
or more alternative telomerase-independent mechanisms exist in human cells [13].
2. Telomerase inhibitors and pharmaceutical importance
Synthesis of DNA at chromosome ends by telomerase may be necessary for indefinite pro-
liferation of human cells. According to results of Kim et al. in cultured cells representing 
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18 different human tissues, 98 of 100 were immortal and none of the 22 mortal populations 
were positive for telomerase. Similarly, 90 of 101 biopsies representing 12 human tumor types 
and none of the 50 normal somatic tissues were positive [14]. Tahara et al. observed that the 
positive telomerase activity in 28 hepatocellular carcinoma (HCC) tissues of 33. Interestingly, 
hepatitis B virus-positive patients were telomerase positive. Also, in 19 of 38 hepatitis tissues 
and 6 of 8 cirrhotic liver tissues, weak telomerase activity was detected. These results indicate 
that the expression of telomerase may play a crucial role in hepatocarcinogenesis [15]. Ferber 
et al. detected that the integrations of the hepatitis B virus and human papillomavirus into 
the hTERT gene in liver and cervical cancers [18]. Hiyama et al. showed that the 95% of the 
advanced stage breast cancer tissues have telomerase activity [16].
Telomerase is a molecular target since its discovery. The most important disadvantage of che-
motherapy drugs used today is that they are not selective, they have effect on normal healthy 
cells together with cancer cells. Telomerase inhibition enables more specific ground because 
the telomerase is not detected in most normal tissues [2, 17]. Differences in telomerase expres-
sion, telomere length, and cell kinetics between normal and cancer tissues suggest that tar-
geting telomerase for cancer therapy may be relatively safe [19]. Telomerase inhibitor effects 
on stem cells may thus be minor because these telomerase-competent cells only proliferate 
intermittently and typically have much longer telomeres than cancer cells [2].
Experimental and clinical studies for telomerase inhibition are currently carried out in many 
different ways, such as inhibition by nucleotides and nucleoside-type reverse transcriptase 
inhibitors; direct inhibition by nonnucleoside small molecules; oligonucleotide inhibitors of 
telomerase activity; gene therapy; telomerase-specific phosphorylation inhibitors; G quadru-
plex stabilizers; and TER directed hammer head ribozymes [2, 17, 20, 21].
In recent studies, some of the synthetic telomerase inhibitors were tried to bone marrow, pros-
tate, brain, breast cancer, and pancreas cancer cells and there was a decrease in the number of 
cancer cells [17]. Telomerase inhibitor imetelstat (GRN163L) is the first telomerase inhibitor to 
advance to the clinical development (www.geron.com/imetelstat). Some izothiazolone deriv-
atives show telomerase inhibition properties [20]. 2-[(E)-3-naphtalen-2-yl-but-2-enoylamino]-
benzoic acid was reported as a selective telomerase inhibitor [20, 22]. According to the results 
of our previous studies (unpublished), some of Imidazo[1, 2-a]pyrazine derivatives can 
be used for telomerase inhibition. There are some studies which draw attention to various 
enzyme inhibition and anticancer activities of İmidazo(1,2-a)pyrazine derivatives [23–28].
In addition to synthetic compounds, various chemical compounds that occur naturally in 
plants like allicin, curcumin, and silbinin have been suggested as telomerase inhibitors (Figures 
1 and 2) [29]. Allicin is organosulfur compound obtained from garlic that can inhibit telomer-
ase activity and induce apoptosis of gastric cancer SGC-7901 cells [30]. Milk thistle’s silymarin 
and silibinin have also been investigated by some researchers in terms of telomerase inhibition 
and activation. The treatment of the K562 human leukemia cell line with silymarin resulted 
in a significant inhibition of telomerase activity [31]. In Yurtcu et al.’s study, combination of 
silymarin and doxorubicin and silymarin alone inhibited telomerase activity in HepG2 hepa-
tocellular carcinoma cell line [32]. But silymarin may activate the telomerase in noncancerous 
cells according to the results of Parzonko et al. In this study, silymarin increased telomerase 
activity in endothelial progenitor cells [33]. Thelen et al. showed that inhibition of telomerase 
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activity by silibinin in prostate cancer cells [34]. Silibinin can also inhibit hTERT gene expres-
sion in T47D breast cancer cells. Silibinin and curcumin combination could be more effective 
in the way of inhibition of telomerase [35]. Curcumin is a  phenolic compound isolated from 
the rhizome of the Curcuma longa L. Curcumin has  antitumor, antiangiogenic, and apoptotic 
Figure 1. Chemical formula of some natural telomerase inhibitors.
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properties. Chakraborty et al. suggested that telomerase inhibition is a main mechanism of 
curcumin-induced apoptosis in human leukemia cell line K-562 [36]. In Ramachandran et al.’s 
study, increasing concentrations of curcumin caused a steady decrease in the level of hTERT 
mRNA and inhibited telomerase activity in MCF-7 breast  cancer cells [37].
Antibiotics oflaxacin and levofloxacin inhibit the telomerase in cell extracts. Helenalin (a nat-
ural sesquiterpene lactone), polyunsaturated fatty acids with cis-double bond, also inhibit 
the telomerase [20]. However, some dietary polyphenols have been suggested as telomer-
ase inhibitors [38]. Major tea catechin epigallocatechin gallate strongly and directly inhibits 
telomerase. It is suggested that telomerase inhibition could be one of the major mechanisms 
underlying the anticancer effects of tea [39]. Naasani et al. proposed that the inhibition of 
telomerase is a key mechanism in cancer inhibition by epigallocatechin gallate [40]. Besides, 
epigallocatechin gallate inhibits telomerase and induces apoptosis in drug resistant lung can-
cer and cervical cancer cells [41, 42]. Epigallocatechin gallate and sulforaphane combination 
treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and 
Bcl-2 downregulation [43]. Sulforaphane (SFN) is a dietary isothiocyanate. SFN decreases via-
bility and telomerase activity in hepatocellular carcinoma Hep3B cells. Moon et al. suggested 
that the reactive oxygen species (ROS) are essential for the suppression of SFN-mediated 
telomerase regulation [44]. According to Meeran et al.’s results, SFN causes epigenetic down-
regulation of hTERT expression in human breast cancer cell lines [45].
Figure 2. Various chemical compounds that occur naturally in garlic, turmeric, grape, and milk thistle are telomerase 
activity modifiers.
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It would suggest that telomerase inhibitors might be most effective in combinations with 
other conventional or experimental cancer treatments [2].
There are alternative mechanisms for telomerase maintenance (ALT) and some rare telomer-
ase negative human cancers. Unfortunately, telomerase inhibitors might result in the emer-
gence of drug resistant telomerase-independent cancer cells [2].
Telomerase inhibitors can be useful for the treatment of some other diseases. Blackburn pro-
posed that telomerase might be target for drugs against eukaryotic pathogenic or parasitic 
microorganisms, such as parasitic protozoans or pathogenic yeast [4]. Actually, some studies 
about telomerase activities of eucaryotic pathogenic microorganisms were achieved. Cano 
and colleagues identified telomerase activity in extracts of Trypanosoma brucei, Leishmania 
major, and Leishmania tarentolae and they proposed as a target the inhibition of telomerase 
activity [46].
The catalytic subunit of telomerase (TERT) shows a striking similarity to retroviral reverse 
transcriptases (retroviral RTs) and viral RNA polymerase [8]. Rubomycin and some of its 
analogs were demonstrated to be potent inhibitors of retroviral RTs and also inhibitors of 
telomerase [20].
Telomerase inhibition is a good and specific target. Because the telomerase is not detected in 
most normal tissues [2, 17], differences in telomerase expression, telomere length, and cell 
kinetics between normal and cancer tissues suggest that targeting telomerase for cancer ther-
apy may be relatively safe [19].
3. Telomerase activators and pharmaceutical importance
Proliferation of telomerase negative cells results in progressive telomere shortening. Cellular 
senescence is thought to serve as a protecting mechanism against cancer, but subsequent telo-
mere dysfunction will be involved in tumorigenesis late in life [20]. Telomere shortening may 
cause aging and death. Some evidence suggests that the progressive loss of telomeric repeats 
of chromosomes may function as a molecular clock that triggers senescence [47–49]. Bodnar 
et al. analyzed two telomerase-negative normal human cell types. The cells were transfected 
with vectors encoding to human telomerase catalytic subunit. Telomerase expressing clones 
had elongated telomeres and showed reduced senescence signs [47]. Numerous epidemio-
logical studies show that shorter telomeres in humans are associated with many age-related 
diseases [49, 50]. Humans with shorter than average telomere length are at risk of dying 
from heart disease, stroke, or infection. Individuals with chronic stress or infections have 
 accelerated telomere shortening compared to age-matched counterparts [51].
Telomerase-related gene mutations result in some diseases. The first disease-associated with 
mutations in human telomerase is dyskeratosis congenita (DKC) [20]. The X-linked form of 
the DKC is caused by mutations in the gene encoding dyskerin (DKC1). It has been suggested 
that DKC may be caused by a defect in rRNA processing. Dyskerin is associated also with 
human telomerase RNA [52]. Autosomal dominant form of DKC is closely associated with the 
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mutations in the TER and defective telomere maintenance [53]. Mitchell et al. find that pri-
mary fibroblasts and lymphoblasts from DKC affected males have a lower level of telomerase 
RNA, produce lower levels of telomerase activity, and have shorter telomeres [52].
More recently, telomerase mutations have been detected in the context of aplastic anemia, 
Hoyeraal-Hreidarsson syndrome, idiopaty pulmonary fibrosis, ataxia telangiectasia, Werner 
syndrome, Bloom syndrome, Nijmegen breakage syndrome, and ataxia telangiectasia-like 
disorder [20, 54]. The unifying molecular characteristics of these diseases are that patients 
harbor telomeres that are significantly shorter than the age-matched control subjects [54]. Not 
only the genetic modulation but also the epigenetic mechanisms may be responsible for the 
diverse expression status of telomerase in a tissue and cell-type dependent manner [55].
Also, telomere erosion occurred by excessive T-cell proliferation in AIDS or X-linked 
Lymphoproliferative syndrome. However, cardiovascular diseases have been recently linked 
with telomere-dependent senescence [20].
Because of that, telomerase activators are important for antiaging and telomerase-dependent 
disease treatments. Telomerase gene therapy in adult and old mice delays aging and increases 
longevity [56, 57]. TERT exhibits neuroprotective effects in experimental models of neurode-
generative disorders suggesting that inducing the telomerase activity in neurons may pro-
tect against age-related neurodegeneration and Alzheimer’s disease [58]. Geron Corp. and 
TA Therapeutics developed a single molecule telomerase activator, TAT2 (cycloastragenol) 
[29]. Cycloastragenol is an aglycone of astragaloside IV (Figure 3). It was first defined when 
screening Astragalus membranaceus extracts for antiaging properties and a potent telomer-
ase activator in neuronal cells [59]. The extract of Astragalus membranaceus was licensed as a 
nutritional supplement called TA 65 (TA sciences, Geron Corp.). This extract could elongate 
short telomeres and increase health span of adult mice without increasing cancer incidence 
[60]. Also, this natural-based product can elongate short telomeres in human leukocytes [61].
Furthermore, certain phytochemicals like resveratrol and genistein have been shown to 
activate telomerase (Figure 3). Genistein is a natural isoflavone found in soybean products. 
Genistein inhibits the transcription of hTERT in breast MCF10AT benign cells and MCF7 can-
cer cells [62]. Genistein also decreases telomerase activity in prostate cancer cells [63, 64]. 
Ouchi et al. showed that the expression of hTERT and c-myc mRNA was downregulated 
by genistein in prostate cancer cells [63]. But, physiologically achievable concentrations of 
genistein enhance telomerase activity in prostate cancer cells [65]. Genistein may activate 
telomerase activity at low concentrations and inhibit telomerase activity at higher treatment 
concentrations [29].
The trans-izomer of resveratrol is a natural phytoalexin present in a limited number of 
Spermatophyta, especially in grapes, fruits, and root extracts. It is synthesized in response 
to stress conditions. Resveratrol has a direct inhibitory effect on cell proliferation. Studies 
showed that resveratrol treatment downregulates the telomerase activity and levels of 
hTERT in MCF7 breast cancer cells [66]. Besides, relatively high concentrations of resveratrol 
were found to be able to downregulate telomerase activity in human colon cancer cells [67]. 
Several compounds like resveratrol have been shown to act as both inhibitors and activators 
Telomerase Inhibitors and Activators: Pharmaceutical Importance
http://dx.doi.org/10.5772/65933
131
of  telomerase though this may be due to treatment concentration or cell type differences. 
Resveratrol has been shown to inhibit telomerase activity in cancer cells but activate telomer-
ase in epithelial and endothelial progenitor cells [29, 68].
There are few studies about the effects of Gingko biloba on telomerase activity. Dong et al. showed 
that Gingko biloba extract increases telomerase activity in endothelial progenitor cell [69].
Also, HMG-CoA reductase inhibitor therapy and statin treatment are associated with delay of 
senescence and reduced cardiovascular diseases [29]. Moreover, in our study (unpublished) 
it was observed that dimetylsulfooxide (DMSO), which is used for solving chemical sub-
stances increases telomerase activity. In the study of Alfonso-De Matte et al., DMSO increased 
 telomerase activity in some cell lines that is known to have no/low telomerase activity [70]. 
Figure 3. Chemical formula of some natural telomerase activators.
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Also, in a study which was carried out about differentiation of embryonic stem cell on rats, 
TERT gene upregulated as a result of dimetylsulfooxide (DMSO) application on each indi-
vidual and telomerase activity increased [71].
Telomere shortening correlates with cellular aging [6]. Telomerase-related gene mutations 
also result in some diseases [20]. Because of that, telomerase activators are important for anti-
aging and telomerase-dependent disease treatments.
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